Kodiak Sciences Shares More Than Double as Wet AMD Drug Zenkuda Meets Primary Goal in Phase 3 DAYBREAK Trial
Kodiak Sciences' shares surged 143% after its wet AMD treatments, Zenkuda and tabirafusp-ted, met primary endpoints in a Phase 3 trial, showing non-inferiority to aflibercept. The company plans regulatory filings by late 2026. Kodiak had $132M in cash at midyear with a $65M quarterly loss. Analysts' price targets range from $36 to $80.
How this was made
The 30-second read
Why it matters
The trial readout is the first public disclosure of pivotal Phase 3 data, prompting a 143% stock surge and setting up upcoming BLA filings.
Market read
First‑report Phase 3 success for a small‑cap biotech, driving a massive intraday rally and setting up regulatory milestones that could reshape the anti‑VEGF market.
What to watch
High short interest (18% of float) could fuel volatility; cash runway is limited, increasing execution risk.
Background
Kodiak Sciences (NASDAQ:KODK) focuses on retinal diseases; its two wet AMD candidates Zenkuda and KSI‑501 are in late‑stage trials.
Market effects
Validates the anti‑VEGF approach and could boost other retinal‑therapy stocks.
U.S. biotech sector may see modest gains as investors reassess late‑stage pipeline risk.
Potential to influence global anti‑VEGF market dynamics, especially in Europe and Asia.
Counterpoint
Some analysts may caution that non‑inferiority does not guarantee market adoption and durability data remain limited.
Key entities
- companyKodiak Sciences
Retina‑focused biotech developing Zenkuda and KSI‑501.
- drugZenkuda (tarcocimab tedromer)
Experimental wet AMD treatment that met primary endpoint.
- drugKSI‑501 (tabirafusp‑ted)
Bispecific antibody also meeting primary endpoint.
